Imugene Ltd (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $490.43 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 7.48 billion
Earnings per share -0.013
Dividend per share N/A
Year To Date Return -37.27%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Imugene Ltd (ASX: IMU)
    Latest News

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    3 ASX healthcare shares outperforming on quarterly updates

    These stocks are charging ahead on an otherwise lacklustre trading day.

    Read more »

    medical asx share price represented by doctor giving thumbs up
    Healthcare Shares

    Broker says this ASX biotech stock could almost double in value

    Bell Potter is feeling very bullish about this risky stock.

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Imugene, Liontown, Pointsbet, and Regis Resources shares are storming higher

    These ASX shares are having a great session. But why?

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Guess which ASX 300 healthcare stock is storming higher on Chinese patent news

    Here's why this healthcare share is catching the eye on Thursday.

    Read more »

    Group of Imugene scientists cheering in the lab after the company received another patent for HER-Vaxx
    Healthcare Shares

    This ASX All Ords healthcare share is leaping 10% on cancer-killing drug trial progress

    Investors are excited over some further news released by the company today.

    Read more »

    Arrows pointing upwards with a man pointing his finger at one.
    Share Gainers

    Why Data#3, Deep Yellow, DroneShield, and Imugene shares are racing higher today

    These ASX shares are catching the eye on Wednesday. But why?

    Read more »

    a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
    Healthcare Shares

    Why is ASX 300 healthcare stock Imugene jumping 14% today?

    Investors are buying this healthcare stock today. But why?

    Read more »

    A man clenches his fists in excitement as gold coins fall from the sky.
    Share Gainers

    Why Collins Foods, Healius, Imugene, and Link shares are climbing today

    These ASX shares are having a stronger day than most on Tuesday.

    Read more »

    Cropped shot of an attractive young female scientist working on her computer in the laboratory.
    Healthcare Shares

    Imugene share price jumps 32% on FDA news

    Here's why this biotech is having a strong start to the session.

    Read more »

    Man drawing an upward line on a bar graph symbolising a rising share price.
    Share Gainers

    Why Avita Medical, Imugene, Pantoro, and Tietto shares are pushing higher

    These ASX shares are having a good finish to the week. But why?

    Read more »

    Three businesspeople leap high with the CBD in the background.
    Healthcare Shares

    Imugene share price jumps 34% on 'major milestone': What is it?

    The healthcare stock is roaring higher again on Friday. But what's getting investors excited?

    Read more »

    A beautiful woman holds up one finger with one hand and has her hand on her waist with the other as she smiles widely as though she is very pleased about something.
    Share Gainers

    Why Imugene, Lottery Corp, Orica, and Sayona Mining shares are storming higher

    These ASX shares are catching the eye on Thursday. But why?

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Ltd

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    IMU Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    22 May 2024 $0.07 $0.00 0.00% 21,034,005 $0.07 $0.07 $0.07
    21 May 2024 $0.07 $0.00 0.00% 20,557,618 $0.07 $0.07 $0.07
    20 May 2024 $0.07 $0.00 0.00% 24,108,291 $0.07 $0.07 $0.07
    17 May 2024 $0.07 $0.00 0.00% 32,544,058 $0.07 $0.08 $0.07
    16 May 2024 $0.07 $0.00 0.00% 11,694,948 $0.07 $0.07 $0.07
    15 May 2024 $0.07 $0.00 0.00% 17,362,151 $0.07 $0.07 $0.07
    14 May 2024 $0.07 $0.00 0.00% 16,987,962 $0.07 $0.07 $0.07
    13 May 2024 $0.07 $0.00 0.00% 40,200,859 $0.08 $0.08 $0.07
    10 May 2024 $0.08 $0.00 0.00% 25,798,902 $0.07 $0.08 $0.07
    09 May 2024 $0.07 $0.00 0.00% 34,239,842 $0.07 $0.07 $0.07
    08 May 2024 $0.08 $0.00 0.00% 16,556,032 $0.08 $0.08 $0.08
    07 May 2024 $0.08 $0.00 0.00% 36,367,534 $0.08 $0.08 $0.08
    06 May 2024 $0.08 $-0.01 -12.20% 24,427,106 $0.08 $0.08 $0.08
    03 May 2024 $0.08 $0.00 0.00% 14,840,107 $0.09 $0.09 $0.08
    02 May 2024 $0.09 $0.00 0.00% 14,369,756 $0.08 $0.09 $0.08
    01 May 2024 $0.08 $0.00 0.00% 24,598,749 $0.09 $0.09 $0.08
    30 Apr 2024 $0.09 $0.00 0.00% 23,957,773 $0.08 $0.09 $0.08
    29 Apr 2024 $0.08 $0.00 0.00% 14,187,753 $0.08 $0.08 $0.08
    26 Apr 2024 $0.08 $0.00 0.00% 17,065,283 $0.08 $0.08 $0.08
    24 Apr 2024 $0.08 $0.00 0.00% 11,486,774 $0.08 $0.09 $0.08
    23 Apr 2024 $0.09 $0.00 0.00% 24,589,293 $0.09 $0.09 $0.08

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    19 Apr 2024 Paul Hopper Sell 5,242,277 $381,113
    On-market trade.
    18 Apr 2024 Paul Hopper Sell 4,500,000 $363,600
    On-market trade.
    17 Apr 2024 Paul Hopper Sell 4,380,952 $365,285
    On-market trade.
    01 Feb 2024 Paul Hopper Issued 110,790,024 $1,717,245
    Issue of securities. Subject to release from escrow, as per announcement on 01-02-2024
    01 Feb 2024 Paul Hopper Issued 1,381,422 $21,412
    Issue of securities. Subject to release from escrow, as per announecment on 01-02-2024
    01 Feb 2024 Paul Hopper Transfer 10,000,000 $1,000,000
    As advised by the company. Transfer of shares for nil
    consideration.
    12 Jan 2024 Paul Hopper Issued 3,901,500 $468,180
    Issue of securities. 3,901,500 - Performance Rights
    12 Jan 2024 Leslie (Mi Ok) Chong Issued 23,175,000 $2,781,000
    Issue of securities. 23,175,000 - Performance Rights
    12 Jan 2024 Lesley Russell Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jens Eckstein Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Jakob Dupont Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    12 Jan 2024 Kim Drapkin Issued 1,000,000 $120,000
    Issue of securities. 1,000,000 - RSUs
    05 Oct 2023 Paul Hopper Issued 535,714 $24,107
    Placement.
    04 Oct 2023 Leslie (Mi Ok) Chong Issued 535,714 $23,571
    Participation in share purchase plan.
    03 Oct 2023 Leslie (Mi Ok) Chong Issued 2,380,952 $199,999
    Placement.
    03 Oct 2023 Leslie (Mi Ok) Chong Issued 2,380,952 $111,904
    Placement.
    03 Oct 2023 Paul Hopper Issued 2,380,952 $111,904
    Placement.
    03 Oct 2023 Paul Hopper Issued 2,380,952 $199,999
    Placement. As per announcement on 04-10-2023
    03 Oct 2023 Lesley Russell Issued 238,095 $19,999
    Placement.
    03 Oct 2023 Lesley Russell Issued 238,095 $11,190
    Placement.
    03 Oct 2023 Kim Drapkin Issued 199,048 $16,720
    Placement.
    03 Oct 2023 Kim Drapkin Issued 199,048 $9,355
    Placement.
    03 Oct 2023 Jakob Dupont Issued 89,286 $7,500
    Placement.
    03 Oct 2023 Jakob Dupont Issued 89,286 $4,196
    Placement.
    03 Oct 2023 Jens Eckstein Issued 238,095 $19,999
    Placement.
    03 Oct 2023 Jens Eckstein Issued 238,095 $11,190
    Placement.
    26 Sep 2023 Paul Hopper Issued 535,714 $29,999
    Placement.
    26 Sep 2023 Leslie (Mi Ok) Chong Issued 535,714 $29,999
    Placement.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Leslie (Mi Ok) Chong Chief Executive OfficerManaging Director Nov 2016
    Ms Chong has over 23 years experience in clinical and department development in oncology. Previously, she was serving at oncology clinical development company, Genentech (a member of the Roche family), as a Senior Clinical Program Lead at the head office in San Francisco. She is also a director of Cure Brain Cancer Foundation (non-profit organisation), since April 2020.
    Mr Paul Alex Hopper Executive ChairmanExecutive Director Dec 2013
    Mr Hopper has over 20 years experience in the management and funding of biotechnology and healthcare public companies as chairman, chief executive officer and director in Australia and the United States. Mr Hopper's sector experience has covered a number of therapeutic areas with a focus on immunotherapy. He also has capital markets experience in equity and debt raisings in Australia, Asia, Europe, and the United States. He is also a former director of Scopus BioPharma Inc.
    Dr Lesley Russell Non-Executive Director Apr 2019
    Dr Russell has over 25 years experience and leadership in the international pharmaceutical field as a Chief Medical Officer. She has undertaken clinical development in a number of therapeutic areas including haematology/oncology has had new drug approvals with both Food and Drug Administration (FDA) and European Medicines Agency (EMA). Dr Russell is a director of Enanta Pharmaceuticals, since 22 November 2016 and former director of Scopus BioPharma Inc, until March 2021. Dr Russell is also a member of Risk Committee.
    Dr Jens Eckstein Non-Executive Director May 2019
    Dr Eckstein has more than 20 years venture capital experience in the biopharmaceutical industry and 10 years operational experience in drug discovery and development. He is a mentor for lifescience entrepreneurs and start-up teams in the area of innovative lifescience and healthcare information technology companies. Before joining Apollo Ventures, Dr Eckstein served as president of SR One for eight years. He is also co-founder and managing director of Action Potential Venture Capital (APVC). Previously, he was a general partner at TVM Capital. Dr Eckstein is also a member of Risk Committee.
    Dr Jakob Dupont Non-Executive Director Sep 2022
    Dr Dupont is an industry and academic drug development expert, specialising in oncology and other therapeutic areas, with more than 20 years of experience. He has made contributions to the development and approval of ten oncology drugs and has orchestrated development programs for numerous drugs. Dr Dupont is currently the Global Head of Research and Development at NASDAQ-listed Atara Biotherapeutics (NASDAQ: ATRA), where he oversees all research and development including three clinical stage programs spanning Phase 1 through to Phase 3, and numerous pre-clinical programs. He also oversees key collaborations with academic and pharma partners, holds leadership and guidance roles for various teams within the business and acts as a spokesperson to investors and the Board of Directors. Prior to Atara, Dr Dupont spent more than six years in various roles at Genentech/Hoffman-La Roche including as Vice President, Global Head of Breast and GYN Cancer Development, in addition to a further five years at Oncomed Pharmaceuticals as Senior Vice President and Chief Medical Officer. Dr Dupont is currently an Independent Director at Apexigen (NASDAQ: APGN) and a Scientific Advisory Board Member at AMBRX (NASDAQ: AMAM). He has been published 48 times in peer-reviewed journals and has established relationships with global clinical and research oncologists, collaborative groups, industry and investors.
    Ms Kim Drapkin Non-Executive Director Jun 2023
    Ms Drapkin has 25 years of experience in the biotechnology and pharmaceutical sectors, Ms Drapkin has a background in finance, capital raising, and strategic financial planning. She held the position of CFO and Treasurer at Jounce Therapeutics, Inc. from 2015 until its acquisition in May 2023, having played a role in the companys growth and financing since its inception. Before joining Jounce, Ms Drapkin managed a financial consulting firm and served as interim CFO for various early-stage biotech companies, including Eleven Biotherapeutics, Inc., NinePoint Medical, Inc., Blueprint Medicines Corporation, Warp Drive Bio LLC, Edimer Pharmaceuticals, Avila Therapeutics, Inc., and Voyager Therapeutics, Inc. Prior to that, she held CFO positions at EPIX Pharmaceuticals and have experience at Millennium Pharmaceuticals. Ms Drapkin also currently serves as the audit committee chair and compensation committee member on Acumen Pharmaceuticals board (NASDAQ: ABOS). Previously, she served on Proteostasis Therapeutics board (NASDAQ: PTI) from 2019 to 2020 and continued on Yumanity Therapeutics board (NASDAQ: YMTX) following its merger with PTI in December 2020 until December 2022. In PTI and Yumanity, she chaired the audit committee and participated in the governance and compensation committees. Ms. Drapkin also served on transaction committees for both companies.
    Mr Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary Mar 2023
    -
    Michael (Mike) Tonroe Chief Financial OfficerCompany Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    J P Morgan Nominees Australia Pty Limited 574,331,818 8.94%
    Hsbc Custody Nominees (Australia) Limited 343,635,691 5.35%
    Mann Family 291,281,412 4.53%
    Citicorp Nominees Pty Limited 277,068,999 4.31%
    Dr Nicholas Smith 118,000,000 1.84%
    National Nominees Limited 114,009,944 1.78%
    Bnp Paribas Noms Pty Ltd 97,615,411 1.52%
    Mi Ok Chong 77,000,000 1.20%
    Netwealth Investments Limited 60,576,704 0.94%
    BNP Paribas Nominees Pty Ltd 29,838,476 0.46%
    Ubs Nominees Pty Ltd 26,929,629 0.42%
    Superhero Securities Limited 24,386,967 0.38%
    Sve Capital Pty Ltd 23,000,000 0.36%
    Buttonwood Nominees Pty Ltd 21,585,740 0.34%
    Dr Jens Eckstein 20,500,000 0.32%
    Dr Lesley Russell 20,000,000 0.31%
    Mr Scott Spencer Pappin & Mrs Tracey Lee Pappin 20,000,000 0.31%
    Mrs Sarah Cameron 19,669,583 0.31%
    Mr James John Shaughnessy & Mrs Margaret Joy Shaughnessy 17,798,374 0.28%
    Dr Nicholas Ede 17,600,000 0.27%

    Profile

    since

    Note